Biotech Inventiva's 50% surge shows investor optimism over liver disease drug

Core Insights - A significant increase in Inventiva shares, approximately 50% in the initial weeks of 2026, indicates strong investor interest in the company despite its current loss-making status [1] Company Summary - Inventiva is a French biotech firm poised to enter a rapidly growing market, attracting attention from investors looking for potential opportunities [1]